

- APOE* gene, 94e-4, 435, 1241, 1241t, 2443
Apo ε gene, 2601
 Apoferritin, 625t
APOL1 gene mutations, 1811, 1832, 1847–1848
APOLI/MYH9 gene, 1241, 1241t, 1630
 Apolipoprotein(a), 2436t, 2437
 Apolipoprotein(s), 2436–2437, 2436t
 Apolipoprotein A-I (ApoA-I), 2436t, 2445, 2757t
 Apolipoprotein A-V (ApoA-V), 2436t, 2440, 2440t
 Apolipoprotein B, 1241t, 2436–2437, 2444, 2757t
 Apolipoprotein B-48, 2436t, 2437
 Apolipoprotein B-100, 2436t, 2437, 2440t, 2442
 Apolipoprotein C, 1241t
 Apolipoprotein C-II (ApoC-II), 2436t
 Apolipoprotein C-II (ApoC-II) deficiency, 2091, 2439–2440, 2440t
 Apolipoprotein E, 2436t, 2437, 2443
 Apomorphine, 263e-6, 2615, 2616t
 Aponeurotic ptosis, 207
 Apoplexy, pituitary, 2257
 Apoptosis
 of cancer cells, 102e-1t, 102e–9, 102e-9f, 103e-6, 103e-7f
 cellular and molecular control of, 372e-23, 372e-26f, 372e-27t
 definition of, 372e-1, 372e-4, 444e-9
 of foam cells, 291e-2
 in HIV infection, 1234
 mitochondria in, 444e-9
 in neurologic disease, 444e-9
 pathways of, 102e-8–9, 102e-9f, 372e-26f
 of red blood cells, 392
 in smoking, 1701
 in viral infection, 214e-6
 Apoptosis proteins, 372e-27t
 Apoptotic bodies, 103e-6
 Apotransferrin, 625
 APP. *See* Amyloid precursor protein (APP)
 Appendectomy, 1988
 Appendiceal fecalith, 1987, 1988f
 Appendiceal neuroendocrine tumors
 (carcinoids), 561t, 563, 567. *See also*
 Gastrointestinal neuroendocrine
 tumors (GI-NETs)
 Appendicitis, **1985**
 clinical features of, 1986–1987
 abdominal pain, 103, 106, 106t, 1986–1987, 1987t
 anorexia, 1987
 atypical patterns, 1987
 classic, 1987t
 nausea and vomiting, 258, 1987, 1987t
 complications of, 1985
 diagnosis of, 1987–1988
 differential diagnosis of, 877, 1986, 1986t
 in the elderly, 1987
 epidemiology of, 1985
 in immunocompromised patients, 1988
 pathogenesis of, 1986
 peritonitis in, 847
 in pregnancy, 1988
 radiographic studies in, 1988f
 treatment of, 1988
 Appendix, 1986, 1986f
 Appetite, 95e-5, 415e-2, 415e-2f
 Appetite suppressants. *See* Anorexiant
APP gene mutations, 172t, 2600–2601
 Apraxia
 in AD, 2599
 buccofacial, 179
 construction, 182
 definition of, 154
 dressing, 182
 gait, 163
 ideational, 179
 ideomotor, 179
 limb, 179
 limb-kinetic, 179
 oculomotor, 181
 of speech, 179
 Apremilast, 2177
 Aprepitant, 103e-25, 109, 260t, 474
 Apriso, 1963
 Aprosodia, 179
 APRT (adenine phosphoribosyltransferase)
 deficiency, 431e-5–6, 431e-5t
 APS. *See* Antiphospholipid syndrome (APS)
 APS-1. *See* Autoimmune polyendocrine
 (polyglandular) syndrome-1 (APS-1)
 APS-2. *See* Autoimmune polyendocrine
 (polyglandular) syndrome-2 (APS-2)
 aPTT. *See* Activated partial thromboplastin time
 (aPTT)
 APUDomas, 557. *See also* Gastrointestinal
 neuroendocrine tumors (GI-NETs)
 Aquagenic urticaria, 2118
 Aquaporins
 AVP action and, 2275, 2276f
 in collecting duct, 332e-9
 in loop of Henle, 332e-8
 in nephrogenic diabetes insipidus, 303, 1872
 in neuromyelitis optica, 2673
 in proximal tubule, 332e-6
 in water balance, 295–296, 296f, 332e-10, 332e-10f
 Araçatuba, 220e-1t, 220e-2
 Arachnidism, necrotic, 2747
 Arachnodactyly, 2512
 Arachnoid cysts, 2264
 Arachnoiditis, lumbar, 117
 Araraquara virus, 1307t
 Araucária virus, 1307t
 Arboviruses, 214e-6, 894
 Arbovirus infections, 892, 894
 ARBs. *See* Angiotensin receptor blockers (ARBs)
Arcanobacterium haemolyticum infections, 129t, 363, 981
 Archaea, in human microbiome, 86e-4
Arcobacter spp. infections, 1059, 1059t
 Arcus corneae, 436e-4f
 ARDS. *See* Acute respiratory distress syndrome
 (ARDS)
 Area postrema (chemoreceptor trigger zone), 258
 Arenaviruses
 global considerations in, 782
 reservoirs and vectors of, 1305, 1306t
 structure of, 214e-2t, 214e-3f, 1305
 Arenavirus infections
 clinical syndromes of, 1306t, 1312t
 geographic distribution of, 1311–1312t
 Junin/Argentinian hemorrhagic fever, 1320
 Lassa fever. *See* Lassa fever
 lymphocytic choriomeningitis (LCM), 891, 893, 908t, 1317–1318
 Machupo/Bolivian hemorrhagic fever, 1320
 Argasid (soft) tick, 2745
 Argatroban
 action of, 754
 discontinuation before lumbar puncture, 443e-1
 for heparin-induced thrombocytopenia, 728, 1461
 monitoring treatment with, 754
 pharmacology of, 753t
 Argentine hemorrhagic fever, 1320
 Arginase deficiency, 434e-3t
 Arginine, 434e-5
 Arginine metabolism disorders, 434e-3t
 Arginine vasopressin (AVP), **2274**
 action of, 2275, 2276f
 in ascites, 286
 for cardiac arrest, 1769, 1769f
 deficiency of
 in diabetes insipidus. *See* Diabetes insipidus
 (DI)
 in hypodipsic hypernatremia, **2279**, 2279f
 ectopic production of. *See* Syndrome of
 inappropriate antidiuretic hormone
 (SIADH)
 in edema, 250
 in heart failure, 1502f
 metabolism of, 2275
 secretion of, 2274–2275
 for septic shock, 1757
 for shock, 1750, 1751
 structure of, 2275f
 synthesis of, 295, 2274
 in thirst, 2275
 in water balance regulation, 64e-6, 295–296, 296f
 Arginine vasopressin (AVP) receptor-2
 antagonists, 2281–2282, 2282f
 Argininosuccinic acidemia, 434e-3t
 Argyll Robertson pupil, 195, 1136
 Argyria, 361
 Aripiprazole, 2721, 2722t
Aristolochia, 14e-4, 1861
 Aristolochic acid nephropathy, 577, 1804, 1856t, 1861
 Armodafinil, 153, 194
 Aromatase deficiency, 337
 Aromatase inhibitors
 action of, 102e-7
 adverse effects of, 103e-15, 2218t, 2492–2493
 for breast cancer, 102e-7, 103e-15, 528–529, 529t, 530t
 for breast cancer prevention, 478, 531
 for male precocious puberty, 2362
 for ovulatory induction, 2389
 Aromatic amines, 477t, 1692
 Aromatic L-amino acid decarboxylase, 372e-24t
 Arousal level, in coma, 1774
 ARR (aldosterone-renin-ratio), 2320t
 Arrhythmogenic right ventricular
 cardiomyopathy (ARVC)
 clinical features of, 1564
 diagnosis of, 1564, 1564f
 genetic considerations in, 1555t
 ventricular arrhythmias in, 1493f, 1495, 1495t
 ARSACS (autosomal recessive spastic ataxia of
 Charlevoix-Saguenay), 451e-3t
 Arsenic exposure/poisoning
 carcinogenicity of, 472e-1, 477t, 506
 clinical features of, 472e-2t, 2608, 2689
 diagnosis of, 472e-2t
 diarrhea in, 267
 global considerations in, 472e-2
 hyperpigmentation in, 361
 laboratory evaluation of, 2766t
 neuropathies in, 2688t, 2689
 optic neuropathy in, 203
 pathophysiology of, 472e-2t
 sources of, 472e-2t
 treatment of, 472e-2t
 Arsenic trioxide, 103e-19t, 686–687
 Arsenine, 262e-1t
 Arteether, 246e-2t, 246e-7
 Artemether
 action of, 246e-7
 adverse effects of, 246e-2t, 1380t
 for malaria, 1378t, 1379, 1380t
 pharmacology of, 246e-7, 1380t
 in pregnancy and lactation, 246e-2t
 resistance to, 1379
 Artemisinin derivatives. *See* Artemether;
 Artesunate
 Arterial blood gases
 abnormal, approach to, 317
 clinical procedure tutorial, 485e-1v
 in hypothermia, 478e-2
 in interstitial lung diseases, 1710
 reference values for, 2757t
 in respiratory disease evaluation, 306e-7, 1663
 Arterial diseases, of extremities
 acrocyanosis, 1442, 1648f, **1649**, 1754
 acute limb ischemia, 1646
 arteriovenous fistula. *See* Arteriovenous fistula
 atheroembolism, 1646, 1646f
 erythromelalgia (erythralgia), 674, 677, 1648f, **1650**
 fibromuscular dysplasia, 1617, 1627, 1645, 2567
 frostbite. *See* Frostbite
 livedo reticularis, 68, 369, 1648f, **1649**, 2135
 peripheral artery disease. *See* Peripheral artery
 disease
 pernio (chilblain), 478e-4, 1648f, **1649**
 popliteal artery aneurysm, 1647